Holen Sie sich die Stockscreener-App
0.421
47.45%
0.1287
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Pasithea Therapeutics announces completion of cohort 7 in ongoing phase 1 trial of PAS-004 - MarketScreener
Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004 - TradingView
Pasithea reports positive safety data from PAS-004 cancer trial - Investing.com
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - Yahoo Finance
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell? - Defense World
Pasithea Therapeutics says positive PAS-004 tablet pharmacokinetic data in ongoing Phase 1/1b trial in adult NF1 patients - MarketScreener
Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients - TradingView
Pasithea Therapeutics' PAS-004 Shows Favorable Pharmacokinetic Properties in Tablets in Phase 1 Trial - MarketScreener
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - Investing News Network
Pasithea reports positive PK data for PAS-004 tablet formulation By Investing.com - Investing.com India
Pasithea reports positive PK data for PAS-004 tablet formulation - Investing.com
Pasithea Therapeutics Announces Positive PAS-004 Tablet - GlobeNewswire
Pasithea Therapeutics Corp. (KTTA) -23.4% in Normal Trading: Despite Positive Phase 1 Data - Stocks Telegraph
Pasithea reports positive interim data for MEK inhibitor in cancer trial - Investing.com Canada
Real time scanner hits for Pasithea Therapeutics Corp. Equity Warrant explainedMarket Growth Summary & Technical Pattern Based Signals - newser.com
Pasithea Therapeutics announces positive phase 1 data including partial response - MarketScreener
Pasithea Therapeutics stock plunges after Phase 1 interim data release By Investing.com - Investing.com Nigeria
Pasithea Therapeutics stock plunges after Phase 1 interim data release - Investing.com
Pasithea reports positive interim data for MEK inhibitor in cancer trial By Investing.com - Investing.com South Africa
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Investing News Network
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Its Stock Has Paid Off Big Time For Pasithea Therapeutics Corp - Setenews
Can Pasithea Therapeutics Corp. Equity Warrant stock resist sector downturns2025 Investor Takeaways & Weekly Consistent Profit Watchlists - newser.com
Why retail investors pile into Pasithea Therapeutics Corp. Equity Warrant stockGap Down & High Conviction Buy Zone Picks - newser.com
Is Pasithea Therapeutics Corp. Equity Warrant stock a buy for dividend growthEarnings Trend Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Why Pasithea Therapeutics Corp. stock is rated strong buy2025 Trade Ideas & Weekly Momentum Picks - newser.com
Does Pasithea Therapeutics Corp. Equity Warrant stock trade at a discount to peers2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Can Pasithea Therapeutics Corp. Equity Warrant stock beat market expectations this quarterFed Meeting & Low Drawdown Trading Strategies - newser.com
Is it too late to sell Pasithea Therapeutics Corp.July 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Pasithea Therapeutics Corp. (KTTA) AI-Powered Stock Analysis - Meyka
Is Pasithea Therapeutics Corp. Equity Warrant stock supported by strong cash flowsRisk Management & Daily Profit Focused Screening - newser.com
Combining price and volume data for Pasithea Therapeutics Corp.Market Risk Report & Daily Stock Momentum Reports - newser.com
Understanding Pasithea Therapeutics Corp. Equity Warrant’s price movementOil Prices & Weekly Watchlist for Consistent Profits - newser.com
Short interest data insights for Pasithea Therapeutics Corp.2025 Price Momentum & Low Risk Entry Point Guides - newser.com
Is Pasithea Therapeutics Corp. stock cheap compared to fundamentalsIndex Update & Stock Portfolio Risk Management - newser.com
Multi factor analysis applied to Pasithea Therapeutics Corp.Trend Reversal & AI Enhanced Execution Alerts - newser.com
Pasithea Therapeutics Corp. stock chart pattern explained2025 Major Catalysts & Verified Momentum Stock Alerts - newser.com
Pasithea Therapeutics Corp. stock trend forecastQuarterly Profit Report & Daily Market Momentum Tracking - newser.com
How currency fluctuations impact Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
[S-1] Pasithea Therapeutics Corp. Files IPO Registration Statement | KTTA SEC FilingForm S-1 - Stock Titan
1.40%
5.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):